7 October 2015 - A clinical trial with shorter follow-up, and larger sample size, generated the greatest expected commercial net benefit. Increasing the duration of follow-up had a modest impact on profit forecasts.

Expected net benefit of sampling can be adapted to value clinical trials in the pharmaceutical industry to optimise the expected commercial net benefit. However, the analyses can be very time consuming for complex CE models.

For more details, go to: http://onlinelibrary.wiley.com/doi/10.1002/hec.3103/abstract?campaign=woletoc